Bullous Pemphigoid (BP)
6
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders